AU Stock MarketDetailed Quotes
IMC Immuron Ltd
- 0.075
- 0.0000.00%
20min DelayMarket Closed Nov 22 15:45 AET
17.10MMarket Cap-2500P/E (Static)
0.076High0.075Low120.69KVolume0.076Open0.075Pre Close9.07KTurnover0.17052wk High0.06%Turnover Ratio228.00MShares0.06552wk Low-0.03EPS TTM14.71MFloat Cap673.436Historical HighLossP/E (Static)196.12MShs Float0.050Historical Low-0.03EPS LYR1.33%Amplitude--Dividend TTM1.34P/B1Lot Size--Div YieldTTM
About Immuron Ltd Company
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
Company Profile
SymbolIMC
Company NameImmuron Ltd
Founded1994
MarketASX
Employees7
Fiscal Year Ends06-30
AddressChapman Street Unit 10, 25-37
CityMelbourne
CountryAustralia
Zip Code3130
Phone+61 398245254
Websitehttps://www.immuron.com.au
Share RegistryAUTOMIC REGISTRY SERVICES
Level 1, 45 Clarence Street, SYDNEY, NSW, AUSTRALIA, 2000
13 25 83
Company Executives
- Name
- Position
- Salary
- Steven Lydeamore
- Chief Executive Officer
- 599.14K
- Dr. Jerry Kanellos, PhD
- Chief Scientific Officer
- 359.25K
- Flavio Palumbo
- Chief Commercial Officer
- 347.61K
- Phillip A. Hains
- Chief Financial Officer and Secretary
- --
- Paul Brennan
- Chairman of the Board
- 153.60K
- Dr. Jeannette Joughin
- Independent Director
- 7.55K
- Professor Ravi Savarirayan
- Independent Director
- 75.00K
- Daniel Pollock
- Independent Director
- 127.65K
Analysis
Price Target
No Data
Heat List
AU
Overall
Symbol
Latest Price
% Chg
No Data